文献速递消化道肿瘤与早癌

METTL3通过m6A-GLUT1-mTORC1轴促进结直肠癌并可作为治疗靶点

RNA N6-Methyladenosine Methyltransferase METTL3 Facilitates Colorectal Cancer by Activating the m6A-GLUT1-mTORC1 Axis and Is a Therapeutic Target.
PubMed 文献 · Gastroenterology · 2020-11-18

该研究探讨m6A甲基转移酶METTL3在结直肠癌中的作用及靶向潜力。METTL3在结直肠癌中高表达且预测不良生存,通过m6A依赖方式诱导GLUT1翻译激活mTORC1,促进肿瘤发生;抑制mTORC1可增强METTL3沉默的抗癌效果。

要点

  • METTL3在结直肠癌中高表达,与不良预后相关。
  • METTL3通过m6A-GLUT1-mTORC1轴促进结直肠癌发展。
  • 靶向METTL3联合mTORC1抑制是潜在治疗策略。

核心结论

  • METTL3通过激活m6A-GLUT1-mTORC1轴促进结直肠癌发展,是潜在治疗靶点。

研究设计与样本

  • 研究利用多个人结直肠癌队列、整合m6A测序、RNA测序和核糖体图谱分析,并在细胞系、患者来源类器官和Mettl3敲除小鼠模型中验证。

主要发现

  • METTL3在62.2%(79/127)和88.0%(44/50)的原发性结直肠癌中过表达。
  • 高METTL3表达预测结直肠癌患者生存不良(n=374,P<.01)。
  • 沉默METTL3抑制结直肠癌细胞、人源原代类器官和Mettl3敲除小鼠模型中的肿瘤发生。
  • METTL3以m6A依赖方式诱导GLUT1翻译,促进葡萄糖摄取和乳酸产生,激活mTORC1信号。
  • 抑制mTORC1增强METTL3沉默在患者来源类器官和METTL3转基因小鼠模型中的抗癌效果。

临床怎么用

  • METTL3高表达可作为结直肠癌预后不良的生物标志物。
  • 靶向METTL3联合mTORC1抑制可能成为结直肠癌治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: RNA N6-methyladenosine (m6A) modification has recently emerged as a new regulatory mechanism in cancer progression. We aimed to explore the role of the m6A regulatory enzyme METTL3 in colorectal cancer (CRC) pathogenesis and its potential as a therapeutic target. METHODS: The expression and clinical implication of METTL3 were investigated in multiple human CRC cohorts. The underlying mechanisms of METTL3 in CRC were investigated by integrative m6A sequencing, RNA sequencing, and ribosome profiling analyses. The efficacy of targeting METTL3 in CRC treatment was elucidated in CRC cell lines, patient-derived CRC organoids, and Mettl3-knockout mouse models. RESULTS: Using targeted clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 dropout screening, we identified METTL3 as the top essential m6A regulatory enzyme in CRC. METTL3 was overexpressed in 62.2% (79/127) and 88.0% (44/50) of primary CRCs from 2 independent cohorts. High METTL3 expression predicted poor survival in patients with CRC (n = 374, P < .01). Functionally, silencing METTL3 suppressed tumorigenesis in CRC cells, human-derived primary CRC organoids, and Mettl3-knockout mouse models. We discovered the novel functional m6A methyltransferase domain of METTL3 in CRC cells by domain-focused CRISPR screening and mutagenesis assays. Mechanistically, METTL3 directly induced the m6A-GLUT1-mTORC1 axis as identified by integrated m6A sequencing, RNA sequencing, ribosome sequencing, and functional validation. METTL3 induced GLUT1 translation in an m6A-dependent manner, which subsequently promoted glucose uptake and lactate production, leading to the activation of mTORC1 signaling and CRC development. Furthermore, inhibition of mTORC1 potentiated the anticancer effect of METTL3 silencing in CRC patient-derived organoids and METTL3 transgenic mouse models. CONCLUSIONS: METTL3 promotes CRC by activating the m6A-GLUT1-mTORC1 axis. METTL3 is a promising therapeutic target for the treatment of CRC.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Chen H, Gao S, Liu W, et al. RNA N6-Methyladenosine Methyltransferase METTL3 Facilitates Colorectal Cancer by Activating the m6A-GLUT1-mTORC1 Axis and Is a Therapeutic Target. Gastroenterology. 2020. PMID: 33217448. doi:10.1053/j.gastro.2020.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。